Alice Melão,  —

Gamida Cell and Editas Medicine have entered a partnership to explore the potential of using gene-editing technology to enhance the activity of certain immune cells against blood and solid cancers. Under the terms of the agreement, the companies will test Editas’ CRISPR technology as a means to engineer Gamida’s…

The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new collaboration between AbbVie, Teneobio, and its affiliate TeneoOne. Under terms of the agreement, TeneoOne will continue to develop TNB-383B through Phase 1 clinical studies,…

A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma patients with stable disease in a Phase 2 study in Japan, researchers report. Data from the 34-patient trial were published in the International Journal of…

Results from the first in-human clinical trial assessing Amgen’s immunotherapy AMG 420 showed promising results in multiple myeloma patients who had received at least two prior lines of therapy. The agent, given at a 400 µg daily dose, reduced tumor burden in 70% of patients, and eliminated even small traces…

Seattle Genetics is recruiting patients with relapsed or refractory multiple myeloma into a Phase 1 clinical trial to study the safety and tolerability of its investigational antibody SEA-BCMA. The study (NCT03582033), which already has dosed its first participant, is being conducted in the United States and is expected…

Treatment with Darzalex (daratumumab) plus standard Revlimid (lenalidomide) and dexamethasone significantly delays the time to disease progression or death in newly diagnosed multiple myeloma patients who are not eligible for high-dose chemotherapy and stem cell transplant, a Phase 3 trial showed. The trial compared the triple combo to treatment…

The U.S. Food and Drug Administration (FDA) has granted priority review to Karyopharm Therapeutics’ application requesting accelerated approval of its investigational therapy selinexor as a treatment for multiple myeloma patients who have failed five prior myeloma therapies. A final decision is expected by April 6, 2019. “As a potential new…

Among those with blood cancers — including myeloma, lymphoma, and leukemia — only 59% fully understand their diagnosis, data from England’s National Cancer Patient Experience Survey reveals. The figure is much lower than the average for other cancer patients, where nearly three in four (73%) say they completely understood their diagnosis.

The U.S. Food and Drug Administration (FDA) has approved Adaptive Biotechnologies’ clonoSEQ Assay to detect and monitor minimal residual disease (MRD) — the small number of cancer cells that remain in a patient’s body during and after treatment — in patients with multiple myeloma and B-cell acute…

SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS) received orphan medicinal product designation from the European Medicines Agency for the treatment of multiple myeloma patients, according to a press release. The decision is expected to support and expedite the clinical development and regulatory review of galinpepimut-S. It provides…